CytoSorbents (Monmouth Junction, N.J.) recently announced that it has received approval from the State of Israel Ministry of Health’s medical device regulation unit for its CytoSorb blood purification technology.
CytoSorb is designed to treat deadly inflammation in critically-ill and cardiac surgery patients.
“We are pleased to bring CytoSorb to Israel, a country well-known for its excellent medical practices, especially in critical care and cardiac surgery, and the development and adoption of new medical technologies,” Vincent Capponi, chief operation officer of CytoSorbents, said in a press release.
The company also announced that Gad Medical will be its Israeli distributor for the CytoSorb technology.
“Now that CytoSorb is registered in Israel, we are excite to work with CytoSorbents on the launch of CytoSorb in the country,” David Frances, CEO of Gad Medical, said in a press release. “Gad Medical specializes in selling cardiovascular medical devices as the exclusive distributor for Term Cardiovascular in Israel, and distributes many new and innovative medical devices in other medical fields. Because of this, we believe we are ideally suited to promote and sell CytoSorb in the country.”
CytoSorb targets the prevention or treatment of the systemic inflammatory response of organ failure in the brain, heart, kidneys and lungs. It is designed to reduce the spread of inflammation, which includes excessive cytokines, bacterial toxins, activated complement, plasma-free hemoglobin, bilirubin and other inflammatory mediators.
